Abstract
Polycystic ovary syndrome (PCOS) presents one of the most widespread endocrine disorders affecting women of reproductive age, predominantly characterized by hyperandrogenism, anovulation, and polycystic ovaries. Women diagnosed with PCOS also present an increased risk for developing metabolic complications like dyslipidemia, metabolic syndrome (MetS) insulin resistance (IR) and type 2 diabetes mellitus. With effective early detection becoming critical to managing these adverse effects, Lipid Accumulation Product (LAP) has emerged as a reliable marker for detecting excessive lipid accumulation beyond adipose tissue, such as in the liver, often associated with cardiometabolic risk; especially among patients with PCOS. This review examines the link between the application of LAP as a predictor of cardiometabolic risks and its association to PCOS, hence seeking possible implementations in clinical settings towards early diagnosis and improved management for affected individuals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
